

strategies and goals, all of which involve substantial risks, uncertainties and assumptions. Such risks, uncertainties and assumptions include, among other things, the uncertainties inherent in determining potential impacts from climate change; changes to existing, or implementation of new regulations; projected financial impact and management cost; and projected performance on climate change related goals. Pfizer's past performance in attaining reductions in greenhouse gas emissions is not an indication of future performance. A further description of risks and uncertainties can be found in Pfizer's Form 10-K for the fiscal year ended December 31, 2019, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results" and in its subsequent reports on Forms 10-Q and 8-K, all of which are filed with the SEC and are available at www.sec.gov and www.pfizer.com.

C0.2

(C0.2) State the start and end date of the year for which you are reporting data.

	Start date	End date	Indicate if you are providing emissions data for past reporting years	Select the number of past reporting years you will be providing emissions data for
Reporting year	January 1, 2019	December 31, 2019	Yes	1 year

C0.3

(C0.3) Select the countries/areas for which you will be supplying data.

- Algeria
- Argentina
- Australia
- Austria
- Belgium
- Brazil
- Canada
- Chile
- China
- Colombia
- Croatia
- Denmark
- Ecuador
- Egypt
- Finland
- France
- Germany
- Greece
- India
- Indonesia
- Ireland
- Italy

Japan
Lebanon
Mexico
Morocco
Netherlands
Pakistan
Portugal
Puerto Rico
Republic of Korea
Russian Federation
Saudi Arabia
Senegal
Singapore
South Africa
Spain
Sweden
Switzerland
Taiwan, Greater China
Tunisia
Turkey
United Kingdom of Great Britain and Northern Ireland
United States of America
Venezuela (Bolivarian Republic of)

C0.4

(C0.4) Select the currency used for all financial information disclosed throughout your response.

USD

C0.5

(C0.5) Select the option that describes the reporting boundary for which climate-related impacts on your business are being reported. Note that this option should align with your chosen approach for consolidating your GHG inventory.

Operational control

C1. Governance

C1.1

(C1.1) Is there board-level oversight of climate-related issues within your organization?

Yes

C1.1a

(C1.1a) Identify the position(s) (do not include any names) of the individual(s) on the board with responsibility for climate-related issues.

Position of individual(s)	Please explain
Board-level committee	The Regulatory & Compliance Committee (RCC) of the Board of Directors receives reports on key risks, including risks related to climate change, from the Pfizer Global Supply (PGS) Quality & Compliance Committee (PGS QCC).
Board-level committee	As reflected in its charter, one of the responsibilities of the Governance & Sustainability Committee (formerly the Governance Committee until 2019) is to maintain an informed status on Company issues related to corporate social responsibility, sustainability, philanthropy, and the Company's participation and visibility as a global corporate citizen. In 2019, during its annual update on corporate social responsibility, the Committee discussed Pfizer's environmental sustainability initiatives and position on climate change with management.
Board-level committee	Pfizer's Enterprise Risk Management (ERM) program provides a framework for risk identification and management of significant risks, including risks related to climate change and the long-term sustainability of the business. Each risk is assigned to a member or members, as appropriate, of our Executive Leadership Team. ERM is conducted at the direction of Legal, and the Audit Committee of the Board of Directors has primary responsibility for overseeing Pfizer's ERM program.
Chief Executive Officer (CEO)	The PGS QCC reports key risks, including those related to climate change to the Executive Compliance Committee (ECC) of Pfizer's Executive Leadership Team, including the CEO.

C1.1b

(C1.1b) Provide further details on the board's oversight of climate-related issues.

Frequency with which climate-related issues are a scheduled agenda item	Governance mechanisms into which climate-related issues are integrated	Please explain
Scheduled – some meetings	<ul style="list-style-type: none"> Reviewing and guiding strategy Reviewing and guiding risk management policies Monitoring implementation and performance of objectives 	The Audit Committee (AC) of the Board of Directors has primary responsibility for overseeing Pfizer's Enterprise Risk Management (ERM) program. The Regulatory and Compliance Committee of the Board (RCC) also joins the ERM meeting with the AC. The ERM program provides a framework for risk identification and management, which includes risks related to climate change.

	<p>Monitoring and overseeing progress against goals and targets for addressing climate-related issues</p>	<p>The PGS QCC reports priority risks, including risks related to climate change, to the RCC.</p> <p>The Governance & Sustainability Committee maintains an informed status of Environmental, Social, Governance (ESG) related matters, which includes Pfizer's climate action and environmental sustainability program and goals.</p> <p>The CEO and Chairman of the Board is responsible, in his capacity as CEO and member of the Executive Leadership Team, for approving environmental sustainability-related public goals.</p>
--	---	--

C1.2

(C1.2) Provide the highest management-level position(s) or committee(s) with responsibility for climate-related issues.

Name of the position(s) and/or committee(s)	Responsibility	Frequency of reporting to the board on climate-related issues
Other C-Suite Officer, please specify CFO & EVP, Global Supply	Both assessing and managing climate-related risks and opportunities	Annually
President	Both assessing and managing climate-related risks and opportunities	Annually
President	Other, please specify Setting capital plans	Annually
Sustainability committee	Other, please specify Overseeing development of next generation goals and strategy	Annually

C1.2a

(C1.2a) Describe where in the organizational structure this/these position(s) and/or committees lie, what their associated responsibilities are, and how climate-related issues are monitored (do not include the names of individuals).

In 2019, Pfizer established a Climate Action & Sustainability Executive Leadership sponsor team to oversee the development of the next generation environmental sustainability strategy and public goals taking the company to 2030. The senior leaders responsible for leading the strategy and goal development process included members from EHS, Engineering, Compliance, Procurement, R&D, Corporate Affairs, and Strategy. Strategy and goals are ultimately approved by the ELT sponsor team and the CEO.

Product manufacturing at our internal network of sites, managed by Pfizer’s Global Supply division (PGS), accounts for 70% of the company’s energy consumption and GHG emissions. The CFO & EVP, Global Supply, leads Pfizer’s manufacturing and supply division and serves as the executive “risk owner” for the company’s business continuity risk and key elements of climate change risk. The President, PGS, reports to the CF) & EVP Global Supply and has operational control over PGS operations and strategy, including OPEX and CAPEX investment in emission reduction projects. Environmental sustainability has been integrated into the overarching PGS strategy and GHG emissions reduction is monitored as a key performance indicator. Performance against this goal is included in a monthly dashboard reviewed by the CFO & EVP.

C1.3

(C1.3) Do you provide incentives for the management of climate-related issues, including the attainment of targets?

	Provide incentives for the management of climate-related issues	Comment
Row 1	Yes	

C1.3a

(C1.3a) Provide further details on the incentives provided for the management of climate-related issues (do not include the names of individuals).

Entitled to incentive	Type of incentive	Activity incentivized	Comment
Other C-Suite Officer	Monetary reward	Emissions reduction target Energy reduction project	Energy savings is a component of overall savings target included in goals against which monetary awards were determined for executive leadership.
Business unit manager	Monetary reward	Emissions reduction target Energy reduction project	Operating unit leaders - target for reduced emissions and contribution toward 20% reduction in GHG emissions (public goal), were included in goals against which monetary awards were determined.
Energy manager	Monetary reward	Emissions reduction target Energy reduction project	Site-specific targets for reduced emissions and contribution toward 20% reduction in GHG emissions (public goal), are included in goals against which monetary awards were determined.

Other, please specify Manufacturing Site Leaders	Monetary reward	Emissions reduction target Energy reduction project	Site-specific target for reduced emissions and contribution toward 20% reduction in GHG emissions (public goal) are included in goals against which monetary awards were determined.
All employees	Non-monetary reward	Emissions reduction project	Colleagues and teams are recognized under the global "Safety and Sustainability STAR Awards Program" for outstanding efforts and projects contributing to and advancing Pfizer's Green Journey, including energy conservation efforts.

C2. Risks and opportunities

C2.1

(C2.1) Does your organization have a process for identifying, assessing, and responding to climate-related risks and opportunities?

Yes

C2.1a

(C2.1a) How does your organization define short-, medium- and long-term time horizons?

	From (years)	To (years)	Comment
Short-term	0	5	
Medium-term	5	10	
Long-term	10	30	

C2.1b

(C2.1b) How does your organization define substantive financial or strategic impact on your business?

For the purposes of this response, Pfizer defines "substantive" climate-related risk as any impact that could adversely impact the company's business or financial condition or disrupt, delay or inhibit the supply of products designated as financially critical, medically necessary, and/or medically significant. For climate-related risks that can be evaluated financially, Pfizer has applied a threshold of \$100MM for considering a risk substantive in this context. Pfizer applies these criteria when assessing both direct and indirect climate-related risks and opportunities. Pfizer also considers areas posing reputational risk to Pfizer.

CDP's phrasing of "substantive" and our response to questions presenting "substantive" risks should not be considered to relate to matters or facts that could be deemed "material" to a

reasonable investor as referred to under U.S. securities laws or similar requirements of other jurisdictions. Investors should refer to disclosures in our Annual Report on Form 10-K (10-K) and in our other filings with the US Securities and Exchange Commission, including our quarterly reports on Form 10-Q and our current reports on Form 8-K, for a discussion of "material" matters.

C2.2

(C2.2) Describe your process(es) for identifying, assessing and responding to climate-related risks and opportunities.

Value chain stage(s) covered

Direct operations
Upstream

Risk management process

Integrated into multi-disciplinary company-wide risk management process

Frequency of assessment

Annually

Time horizon(s) covered

Short-term
Medium-term
Long-term

Description of process

Pfizer assesses climate change risk as part of our Enterprise Level EHS & Business Continuity Risk Management Process. Under this process, we conduct Operational Risk Evaluations (OREs) which are structured evaluations of risks with the potential to have substantive impact to Pfizer. The process evaluates the controls in place to manage or mitigate the risk and a determination of the adequacy of the control of risk. Climate change risk is evaluated by a team that includes relevant program leaders and subject matter experts from EHS and Business Resilience, Engineering, Compliance, Environmental Law, and Audit.

The annual Climate Change ORE is designed to assess potential risk to Pfizer across four risk factors, including: External/Reputational, Physical, Regulatory/Legal, and Market & Technology Risks. Individual risks across each of the four risk factors are evaluated and rated based on the severity, vulnerability, and risk to Pfizer with the goal to ensure that sufficient controls are in place to effectively mitigate climate change risks and prevent material impact to Pfizer.

Using the ORE, we assess risk factors based on the severity and vulnerability. We define high severity as loss of the capability to produce products as the result of extensive damage, shut-down, or substantial loss of plant. We define high vulnerability

as controls that are not as robust as would be reasonably expected across multiple layers, suggesting increased potential for significant failure of risk control. The higher the severity and the vulnerability, the higher we define overall risk. Based on the risk scores, we prioritize action. Of all the TCFD categories of climate risks, we have determined the most significant potential threat related to our operations is physical risk.

Pfizer uses tools such as Swiss Re CatNet to monitor short-, medium- and long-term physical threats to internal operations and for more than 5,000 contract manufacturers and material suppliers. Risks identified through these assessments are reviewed as part of the ORE, and mitigation of risk is monitored through Pfizer's Business Resilience program and escalated to company leadership as needed to inform business strategy.

C2.2a

(C2.2a) Which risk types are considered in your organization's climate-related risk assessments?

	Relevance & inclusion	Please explain
Current regulation	Relevant, always included	Pfizer assesses the impacts of existing regulatory requirements and voluntary agreements as part of our risk review. We look at current regulation pertaining to voluntary agreements, existing or emerging market-based regulatory requirements to lower emissions, renewable energy standards, and other environmental legislation/regulations. To manage and reduce risk, in our most recent review we assessed the effectiveness of our internal environmental impact reduction requirements and our voluntary GHG reduction goals to ensure conformance in regions which have already implemented cap-and-trade requirements. Pfizer is acting independently to help achieve the initial goals set through the Paris Agreement. An example of this is our monitoring process for existing cap-and-trade programs that apply to our operations in Ireland and Italy, which are subject to the EU ETS.
Emerging regulation	Relevant, always included	<p>Pfizer assesses the impacts of emerging regulatory requirements and voluntary agreements as part of our risk review, such as the potential impacts on our operations of the implementation of a carbon tax in the US and/or cap-and-trade programs in China.</p> <p>Beyond just tracking emerging regulation, Pfizer is committed to taking voluntary action to reduce our carbon footprint. In 2019, Pfizer established a cross-functional team to develop next (fourth) generation (post 2020) climate goals aligned with science. We plan to announce a new goal when we reach the conclusion of our current third generation GHG reduction goal.</p>

Technology	Relevant, always included	Pfizer assesses the impacts of changing technology on its operations as part of the risk review. Our most recent review included an assessment of the impact of the phase-out of high Global Warming Potential refrigerants on our operations. As we look forward, we are also monitoring the benefits of new technologies to increase the efficiency of our operations to enable maintenance of competitiveness in the event of energy cost increases. Beyond our programs to reward GHG reduction at all employee levels in the organization, we also challenge our operational teams to identify opportunities for technological improvements. In 2019 we provided certified energy manager training and energy/utility resilience coaching to our site utility engineers to improve their abilities to develop and implement effective energy management and emission reduction strategies.
Legal	Not relevant, included	Pfizer has not received any climate-related litigation claims but does consider the potential for such claims as part of the risk review. Given the relatively limited climate-related regulation covering our operations, as well as our proactive efforts to reduce GHG emissions, we believe we are well positioned to meet future external regulatory/legal requirements with limited legal risk.
Market	Relevant, always included	Climate change could have a ripple effect on the availability of natural resources or shifting of disease patterns. The World Health Organization (WHO) projects that by 2050, climate change may cause 250,000 additional deaths per year from malnutrition, malaria, diarrhea and heat stress. With an extensive portfolio and expansive geographic reach, we have been able to consistently meet the diverse needs of, and provide significant value and impact to, patients and health care professionals around the world in an innovative, socially responsible and commercially viable manner. To integrate this risk, Pfizer continues to monitor published reports from the Centers for Disease Control (CDC) and WHO on projections of health impacts.
Reputation	Relevant, always included	Our risk review considers potential risk to reputation if we do not meet stakeholder expectations on voluntary disclosures, policy position, and alignment on climate change policy with trade associations. We are committed to providing transparency to our actions, including extensive reporting on our climate action strategies through our website, Annual Review, and the annual CDP response. Through these formats, we communicate with our stakeholders about the actions that we are taking to manage climate change risks. Several of our sites have been recognized by external stakeholders for their environmental efforts. For example, our Vizag site's commitment to environmental sustainability was recognized at the December 2019 India HSE Summit & Awards, and our Grange Castle, Ireland site's energy reduction program was awarded an IMR Manufacturing and Supply Chain Award by Irish Manufacturing Research in January 2020.

Acute physical	Relevant, always included	Our Business Resilience risk review process addresses the potential impacts of acute and chronic physical risks on our operations and those of our direct material suppliers. As part of this program, we conduct detailed risk reviews to assess acute and chronic physical risk for our manufacturing facilities and material suppliers. Our assessment process utilizes available models to assess risk associated with earthquakes, windstorms, floods, storm surge, drought/water scarcity, severe weather, wildfires, volcanos and tsunamis. We have completed these assessments for all our internal manufacturing facilities and for over 5,000 of our contract manufacturers and material suppliers, and we refresh this assessment annually. We are currently working to develop and implement risk reduction plans for areas of elevated acute risk, such as at our Puerto Rico facilities where we experienced detrimental impacts as a result of Hurricane Maria in 2017.
Chronic physical	Relevant, always included	Our Business Resilience risk review process addresses the potential impacts of acute and chronic physical risks on our operations and those of our direct material suppliers. In 2018 we initiated a detailed risk review process to assess acute and chronic physical risk for our manufacturing facilities and material suppliers. Our assessment process utilizes available models to assess risk associated with earthquakes, windstorms, floods, storm surge, drought/water scarcity, severe weather, wildfires, volcanos and tsunamis. We have completed these assessments for all our internal manufacturing facilities and for over 5,000 of our contract manufacturers and material suppliers, and we refresh this assessment annually. One example of chronic risk considered as part of business strategy was the analysis of flooding risk when selecting a location for a new R&D facility in Durham, North Carolina. Modeling was used to inform site selection and to identify risk mitigation measures to be included in the capital plan.

C2.3

(C2.3) Have you identified any inherent climate-related risks with the potential to have a substantive financial or strategic impact on your business?

Yes

C2.3a

(C2.3a) Provide details of risks identified with the potential to have a substantive financial or strategic impact on your business.

Identifier

Risk 1

Where in the value chain does the risk driver occur?

Direct operations

Risk type & Primary climate-related risk driver

Emerging regulation
Carbon pricing mechanisms

Primary potential financial impact

Increased indirect (operating) costs

Company-specific description

Following the Paris Agreement, more than 40 nations and over 20 other jurisdictions have begun putting a price on carbon emissions. Although not financially substantive to our operations at this time, it potentially has strategic impact. The \$5/ton tax recently levied in Singapore for facilities exceeding 25,000 tons of GHG emissions has increased the site's energy spend by approximately 3%. The implementation of a US tax such as that proposed by Americans for Carbon Dividends or the Climate Leadership Council could increase Pfizer's operational cost (direct costs associated with internal sites and fleet and indirect costs associated with charge-back from external suppliers) by ~25%. Other regions where Pfizer operates have indicated future intentions to implement carbon pricing. To mitigate the impact from carbon fees, Pfizer continues to focus on energy demand reduction through our GHG reduction goals (recognized through the Science Based Targets initiative) and is currently working to establish next generation GHG reduction goals aligned with science.

Time horizon

Medium-term

Likelihood

Very likely

Magnitude of impact

Medium-low

Are you able to provide a potential financial impact figure?

Yes, an estimated range

Potential financial impact figure (currency)

Potential financial impact figure – minimum (currency)

160,000

Potential financial impact figure – maximum (currency)

4,300,000

Explanation of financial impact figure

Estimated costs associated with the implementation of new carbon taxes and/or cap-and-trade schemes in regions where we operate, including the United States, Singapore and China.

Cost of response to risk

50,000,000

Description of response and explanation of cost calculation

Pfizer evaluates climate change risk as part of its operating risk review process. We monitor regulatory risks arising from current and/or expected local, state, regional, national or global governmental regulations or legislation related to climate change and evaluate the impact on an ongoing basis. Pfizer's Climate Change Position Statement (used to evaluate and position the company relative to emerging legislation/regulation); an internal EHS regulatory tracking and emerging issues alert process; Pfizer's internal audit program to ensure compliance with regulatory requirements and site EHS colleagues to manage implementation. In addition, Pfizer manages risk associated with emerging regulation and/or carbon pricing initiatives through the following: effective GHG reduction goals and internal energy efficiency targets to reduce potential costs associated with purchase or generation of energy.

Comment

Integrated into staff costs and membership dues which are estimated to be <0.05% of total 2019 revenue (\$51.8bn) on an annual basis. Energy efficiency project OPEX and CAPEX costs for 2019 were \$27MM.

Identifier

Risk 2

Where in the value chain does the risk driver occur?

Direct operations

Risk type & Primary climate-related risk driver

Acute physical

Increased severity and frequency of extreme weather events such as cyclones and floods

Primary potential financial impact

Decreased revenues due to reduced production capacity

Company-specific description

Climate change presents risks to our operations, including the potential for more frequent and severe weather events and water availability challenges that may impact our facilities and those of our suppliers. For example, in 2017, our manufacturing and commercial operations in Puerto Rico were impacted by hurricanes.

To evaluate the potential impacts from severe weather events, Pfizer uses a detailed risk review process to assess acute and chronic physical risk for our manufacturing facilities and material suppliers. Our assessment process utilizes available models to assess short, medium and long-term risk associated with earthquakes, windstorms, floods, storm surge, drought/water scarcity, severe weather, wildfires, volcanos and

tsunamis. We complete these assessments for all our internal manufacturing facilities and for over 5,000 of our contract manufacturers and material suppliers. We are currently developing and implementing risk reduction plans for areas of identified risk.

We cannot provide assurance that physical risks to our facilities and supply chain due to climate change will not occur in the future. To date, however, our assessments indicate that because of our geographical locations, our supply chain contingencies, and our risk mitigation measures, these risks are not anticipated to have a near term material impact on Pfizer.

Time horizon

Medium-term

Likelihood

Unlikely

Magnitude of impact

Medium-low

Are you able to provide a potential financial impact figure?

Yes, a single figure estimate

Potential financial impact figure (currency)

100,000,000

Potential financial impact figure – minimum (currency)

Potential financial impact figure – maximum (currency)

Explanation of financial impact figure

The potential financial loss we could reasonably expect as a result of property damage and business interruption at any of Pfizer's facilities in Puerto Rico.

Cost of response to risk

2,000,000

Description of response and explanation of cost calculation

Pfizer's Business Continuity program identifies potential supply chain vulnerabilities and establishes contingency plans to maintain supply. For example, alternative sourcing options and holding multiple weeks of buffer inventory (depending on product).

Comment

Pfizer maintains resources for assessing and putting in place business continuity arrangements such as the activation of alternative supply chains. Supply chain and business continuity professionals are retained as staff and consultants to ensure that Pfizer's supply chain is sufficiently resilient. Integrated into existing budgets; estimated direct staff costs of \$2MM.

Identifier

Risk 3

Where in the value chain does the risk driver occur?

Direct operations

Risk type & Primary climate-related risk driver

Reputation

Increased stakeholder concern or negative stakeholder feedback

Primary potential financial impact

Decreased revenues due to reduced demand for products and services

Company-specific description

Although not financially substantive, Pfizer's participation in various industry associations does have a potential reputational impact because certain stakeholders disagree with the environmental positions of these organizations and those organizations' positions are not reflective of Pfizer's positions. We are committed to voicing our concerns and views as appropriate through representatives on the boards and committees of these groups. For example, Pfizer is one of a number of "like-minded" companies that in 2017 established the Climate Solutions Working Group (CSWG), an informal group of U.S. Chamber of Commerce member companies, for the purpose of advancing business interests in climate change solutions and engaging within the Chamber on climate change issues. The CSWG worked with the U.S. Chamber of Commerce to influence the Chamber's 2019 climate policy statement. The statement, while a document of compromise, makes clear that climate change is a serious issue, a risk to businesses, and that inaction is not an option. The Chamber established a Task Force on Climate Actions in 2019 and Pfizer is participating consistent with our position on the need for climate change mitigation.

Time horizon

Medium-term

Likelihood

About as likely as not

Magnitude of impact

Low

Are you able to provide a potential financial impact figure?

Yes, an estimated range

Potential financial impact figure (currency)

Potential financial impact figure – minimum (currency)

500,000

Potential financial impact figure – maximum (currency)

5,000,000

Explanation of financial impact figure

It can be difficult to directly correlate financial implications resulting from potentially negative impact to reputation. The range of \$500,000 - \$5M includes engagement time with stakeholders, the shareholder proposal process, legal evaluation, SEC reporting and inclusion of a proposal within the annual proxy statement.

Cost of response to risk

10,000

Description of response and explanation of cost calculation

In conjunction with Corporate Affairs, Investor Relations, and the Corporate Secretary, Pfizer conducts stakeholder engagement sessions annually with impact and mainstream investors. These sessions provide useful insights into concerns regarding our involvement in various organizations and the effectiveness of our efforts to influence these organizations.

Comment

There are minimal costs associated with managing this risk. Pfizer leverages its internal social networking tools and SharePoint sites to distribute timely information on market developments and changing consumer behaviors. There are only minor costs associated with monitoring these developments, such as the costs of organizational memberships, conference fees, and subscriptions to trade newsletters.

C2.4

(C2.4) Have you identified any climate-related opportunities with the potential to have a substantive financial or strategic impact on your business?

Yes

C2.4a

(C2.4a) Provide details of opportunities identified with the potential to have a substantive financial or strategic impact on your business.

Identifier

Opp1

Where in the value chain does the opportunity occur?

Direct operations

Opportunity type

Products and services

Primary climate-related opportunity driver

Development of new products or services through R&D and innovation

Primary potential financial impact

Increased revenues resulting from increased demand for products and services

Company-specific description

The WHO projects that by 2050, climate change may cause 250,000 additional deaths per year from malnutrition, malaria, diarrhea and heat stress. With an extensive portfolio and expansive geographic reach, we have been able to consistently meet the diverse needs of, and provide significant value and impact to, patients and health care professionals around the world in an innovative, socially responsible and commercially viable manner. We have large, diverse portfolios of anti-infective therapies with more than 80 life-saving medicines.

Time horizon

Medium-term

Likelihood

About as likely as not

Magnitude of impact

Low

Are you able to provide a potential financial impact figure?

No, we do not have this figure

Potential financial impact figure (currency)

Potential financial impact figure – minimum (currency)

Potential financial impact figure – maximum (currency)

Explanation of financial impact figure

The potential financial implications of this opportunity are unknown; however, there could be an increased demand for products related to diseases impacted by climate change.

Cost to realize opportunity

0

Strategy to realize opportunity and explanation of cost calculation

Our overall Corporate Responsibility program is well poised to address the potential opportunities climate change may present with respect to health. Pfizer combines traditional philanthropic methods with novel approaches that create an enduring and meaningful impact on public-health systems to facilitate access to healthcare for underserved communities around the world. Recognizing the critical need in settings requiring relief and emergency humanitarian assistance, Pfizer has a three part approach,

including product donations, cash grants, and other access solutions. Our work makes the best use of Pfizer's resources—our people, products, and funding—to address complex healthcare challenges. These efforts would not be possible without our partnerships with non-profit organizations, governments, and foundations. Our portfolio of programs ranges from donating Pfizer medicines and volunteering valuable employee skills to providing grants and investments that support social entrepreneurs and enterprises, fostering local innovation and improving healthcare delivery and access.

Comment

The costs associated with these actions are not easily determined at this time.

Identifier

Opp2

Where in the value chain does the opportunity occur?

Direct operations

Opportunity type

Resource efficiency

Primary climate-related opportunity driver

Use of more efficient production and distribution processes

Primary potential financial impact

Reduced indirect (operating) costs

Company-specific description

Pfizer continually drives the improvement of efficiency of our operations. Through more than 4,000 conservation projects, we have reduced our GHG emissions by ~60% since 2000 and are on our way to achieve our 2020 goal which will keep us on the trajectory to reach a 75% reduction by 2050 (our current Science Based Target). We are establishing our next generation (post 2020) climate action strategy to continue to deliver reductions. At the product level, green chemistry (the design of chemical products and processes that reduce or eliminate the use and generation of hazardous substances) delivers process efficiencies and reductions in product environmental footprint.

Time horizon

Short-term

Likelihood

Virtually certain

Magnitude of impact

Medium-low

Are you able to provide a potential financial impact figure?

Yes, an estimated range

Potential financial impact figure (currency)

Potential financial impact figure – minimum (currency)

3,000,000

Potential financial impact figure – maximum (currency)

5,000,000

Explanation of financial impact figure

Pfizer achieves an annual savings of \$3-5MM per year through the implementation of emission reduction projects. These projects typically have a payback of period of 4-6 years or less and have a lifetime greater than 6 years.

Cost to realize opportunity

20,000,000

Strategy to realize opportunity and explanation of cost calculation

Pfizer's Environmental Sustainability and Impact Reduction Standard requires all sites to develop a systematic approach to conserve energy and improve efficiency. Sites identified as medium and large energy users are required to establish environmental sustainability teams and to develop and maintain sustainability master plans that include prioritized emission reduction opportunities. Project implementation is monitored at the corporate level with performance reports provided to company leadership quarterly.

Comment

Pfizer invests an estimated \$20-25M each year to reduce energy demand through asset replacement, efficiency improvements, and installation of renewable technologies.

Identifier

Opp3

Where in the value chain does the opportunity occur?

Opportunity type

Markets

Primary climate-related opportunity driver

Use of public-sector incentives

Primary potential financial impact

Increased revenues through access to new and emerging markets

Company-specific description

Our current and potential customers increasingly request and rate our environmental program to support their own efforts to address climate change. In 2019 Pfizer provided GHG emissions and environmental sustainability program information to 11 customers

and for several hospital tenders in Europe. As of mid-year 2020 we have already received over 20 requests. While the amount of influence Pfizer's environmental sustainability performance has on our customers' purchasing decisions is not known, the revenue associated with customers requesting this information exceeds \$100MM.

Time horizon

Short-term

Likelihood

Very likely

Magnitude of impact

Medium-low

Are you able to provide a potential financial impact figure?

Yes, a single figure estimate

Potential financial impact figure (currency)

100,000,000

Potential financial impact figure – minimum (currency)

Potential financial impact figure – maximum (currency)

Explanation of financial impact figure

Pfizer continues to see increased requests for environmental information for more products and by more customers. The revenue associated with customers requesting this information exceeds \$100MM.

Cost to realize opportunity

0

Strategy to realize opportunity and explanation of cost calculation

Pfizer's Global EHS team responds to these requests with support from other Pfizer teams and site colleagues. The costs associated with preparing these responses are integrated into staff costs.

Comment

C3. Business Strategy

C3.1

(C3.1) Have climate-related risks and opportunities influenced your organization's strategy and/or financial planning?

Yes, and we have developed a low-carbon transition plan

C3.1a

(C3.1a) Does your organization use climate-related scenario analysis to inform its strategy?

No, but we anticipate using qualitative and/or quantitative analysis in the next two years

C3.1c

(C3.1c) Why does your organization not use climate-related scenario analysis to inform its strategy?

i. Why scenario analysis is not currently used to inform our enterprise level business strategy
Pfizer has a program for reviewing our vulnerability to potential weather-related risks at our facilities and in our supply chain. These assessments are updated periodically. At the asset level, assessment of risks is managed through Pfizer’s Insurance and Business Continuity teams both at the enterprise and local level. Members from those teams participate in the risk review process that addresses Business Continuity/Resiliency and provide input on the potential impact of physical risks that may be related to climate change (e.g. severe weather events, flooding).

ii. Future plans

Pfizer maintains assessments of acute and chronic physical risk for all our manufacturing facilities and for over 5,000 of our contract manufacturers and material suppliers. The output of this predictive analysis will support inclusion of climate-related scenario analysis into business strategy development going forward.

C3.1d

(C3.1d) Describe where and how climate-related risks and opportunities have influenced your strategy.

	Have climate-related risks and opportunities influenced your strategy in this area?	Description of influence
Products and services	Yes	Pfizer has leveraged our achievements in green chemistry, success with our public GHG reduction goals, and commitment to Science Based Targets to develop substantiated green claims which have been shared with potential customers/retailers and governmental tenders.
Supply chain and/or value chain	Yes	Pfizer has requested 150 key suppliers to provide information on their efforts to manage greenhouse gas emissions and adopt reduction targets as indicated in our risk table. Furthermore, our cross functional Operational Risk Review process includes an assessment of climate change risk in the supply chain. In 2017 our supply chain

		was impacted as a result of Hurricane Maria in Puerto Rico, however dual source supply options and sufficient pre-hurricane inventory level limited the impact.
Investment in R&D	Not evaluated	Pfizer continues to monitor published reports from the Centers for Disease Control and Prevention (CDC) and WHO on projections of health impacts. Pfizer's portfolio includes many products and a wide range of medicines that might be used to treat the associated conditions.
Operations	Yes	To achieve our public goals for greenhouse gas reductions, Pfizer has implemented numerous efficiency improvements to our operations. In 2019 we initiated a five-year program to deploy digital monitoring systems to improve the resiliency of equipment and reduce GHG emissions from our manufacturing sites.

C3.1e

(C3.1e) Describe where and how climate-related risks and opportunities have influenced your financial planning.

	Financial planning elements that have been influenced	Description of influence
Row 1	Revenues Indirect costs Capital expenditures Acquisitions and divestments Access to capital Assets	<p>Earlier this year, Pfizer completed a \$1.25 billion ten-year sustainability bond, a first for a biopharmaceutical company. Proceeds from the bond will be used to help manage our environmental impact and support increased patient access to Pfizer's medicines and vaccines, especially among underserved populations, and strengthen healthcare systems. See Pfizer's website for more information on the bond framework: https://pfe-pfizercom-d8-prod.s3.amazonaws.com/SustainabilityBondFramework.pdf</p> <p>Pfizer receives numerous requests for environmental performance information from current customers and as part of tenders. While the level of influence that our environmental performance has on customer purchasing decisions is not known, the number of customer and tender inquiries increases each year. The revenue associated with customers requesting this information is more than \$100M for pharmaceutical products and is factored into revenue forecasts.</p> <p>Annual targets are established for program savings. Our medium and large sites are required to maintain master plans that identify opportunities for emission reductions. These projects are reviewed through our capital project</p>

		<p>appropriation process. The costs to implement these projects as well as the expected cost savings are included in the site's operating budgets and/or capital plans as appropriate. These savings are typically around \$3-5MM per year. Projects implemented in 2019 include the installation of new boilers and HVAC systems as well as chiller optimization at several of our manufacturing sites, resulting in a savings of \$2MM and a 47,500 mT CO2e GHG reduction.</p> <p>Pfizer requires newly acquired facilities to establish, resource and maintain business continuity management programs.</p> <p>Costs to maintain Pfizer's risk engineering provider is estimated at \$0.3MM annually. Costs relating to property protection and supply chain management are annualized, expected to be incurred annually and are incorporated into existing budgets. Site protection systems improvements and maintenance costs are estimated at \$0.1MM. Direct staff costs related to managing this risk is estimated at \$2.0MM.</p>
--	--	--

C3.1f

(C3.1f) Provide any additional information on how climate-related risks and opportunities have influenced your strategy and financial planning (optional).

C4. Targets and performance

C4.1

(C4.1) Did you have an emissions target that was active in the reporting year?

Absolute target

C4.1a

(C4.1a) Provide details of your absolute emissions target(s) and progress made against those targets.

Target reference number

Abs 1

Year target was set

2013

Target coverage

Company-wide

Scope(s) (or Scope 3 category)

Scope 1+2 (location-based)

Base year

2012

Covered emissions in base year (metric tons CO₂e)

2,005,730

Covered emissions in base year as % of total base year emissions in selected Scope(s) (or Scope 3 category)

100

Target year

2020

Targeted reduction from base year (%)

20

Covered emissions in target year (metric tons CO₂e) [auto-calculated]

1,604,584

Covered emissions in reporting year (metric tons CO₂e)

1,496,924

% of target achieved [auto-calculated]

126.8381088182

Target status in reporting year

Underway

Is this a science-based target?

Yes, this target has been approved as science-based by the Science-Based Targets initiative

Please explain (including target coverage)

We have achieved a >20% reduction, however since energy use and GHG emissions were projected to increase slightly in 2020 as a result of production increases, we have decided not to claim goal achievement until the end of the goal period. Driving operational improvements through capital projects, operational efficiency improvements and transformative efforts (e.g., new manufacturing technology) remains the cornerstone of our focus.

Target reference number

Abs 2

Year target was set

2002

Target coverage

Company-wide

Scope(s) (or Scope 3 category)

Scope 1+2 (location-based)

Base year

2000

Covered emissions in base year (metric tons CO₂e)

3,479,388

Covered emissions in base year as % of total base year emissions in selected Scope(s) (or Scope 3 category)

100

Target year

2050

Targeted reduction from base year (%)

60

Covered emissions in target year (metric tons CO₂e) [auto-calculated]

1,391,755.2

Covered emissions in reporting year (metric tons CO₂e)

1,496,924

% of target achieved [auto-calculated]

94.9622941353

Target status in reporting year

Underway

Is this a science-based target?

Yes, this target has been approved as science-based by the Science-Based Targets initiative

Please explain (including target coverage)

Pfizer has an aspirational goal of reducing our GHG footprint 60-80% by 2050 from a 2000 base year. To achieve this Pfizer sets shorter term goals and has previously achieved two GHG reduction goals (2000-2007 and 2007-2012). It is our intention to continue this process of setting interim goals that help drive towards this larger goal that aligns with the level of ambition needed to limit global temperature rise.

C4.2

(C4.2) Did you have any other climate-related targets that were active in the reporting year?

No other climate-related targets

C4.3

(C4.3) Did you have emissions reduction initiatives that were active within the reporting year? Note that this can include those in the planning and/or implementation phases.

Yes

C4.3a

(C4.3a) Identify the total number of initiatives at each stage of development, and for those in the implementation stages, the estimated CO2e savings.

	Number of initiatives	Total estimated annual CO2e savings in metric tonnes CO2e (only for rows marked *)
Under investigation	29	3,944.52
To be implemented*	1	35.34
Implementation commenced*	43	4,160.28
Implemented*	66	47,543.2
Not to be implemented	85	19,796.6

C4.3b

(C4.3b) Provide details on the initiatives implemented in the reporting year in the table below.

Initiative category & Initiative type

Energy efficiency in buildings

Other, please specify

HVAC, lighting and other improvements

Estimated annual CO2e savings (metric tonnes CO2e)

47,543.2

Scope(s)

Scope 1

Scope 2 (location-based)

Voluntary/Mandatory

Voluntary

Annual monetary savings (unit currency – as specified in C0.4)

1,932,671

Investment required (unit currency – as specified in C0.4)

27,171,593

Payback period

4-10 years

Estimated lifetime of the initiative

6-10 years

Comment

Multiple initiatives across Pfizer

C4.3c

(C4.3c) What methods do you use to drive investment in emissions reduction activities?

Method	Comment
Compliance with regulatory requirements/standards	Pfizer prioritizes funding for projects that reduce energy demand and GHG emissions associated with regulatory compliance requirements.
Internal incentives/recognition programs	Pfizer's internal awards program called "Safety and Sustainability STAR Awards" recognizes employees' projects across Pfizer related to driving sustainability improvements including demand and GHG reductions, green biotech and chemistry. These awards encourage sites to implement sustainability initiatives. In 2019, 5 projects were awarded STARS for environmental sustainability achievements.
Lower return on investment (ROI) specification	Projects with environmental benefits may be approved for funding in spite of not meeting internally established standard hurdle rates. Recent examples include the installation of new natural gas boilers to eliminate the use of coal at our Kalamazoo, Michigan site; the installation of a photovoltaic system at our Puurs, Belgium site; and a solar thermal installation at our Freiburg, Germany site. The latter two projects have payback periods much longer than Pfizer's standard expectation of 2-3 years (10 years for the photovoltaic project and 10-15 years for the Freiburg project).

C4.5

(C4.5) Do you classify any of your existing goods and/or services as low-carbon products or do they enable a third party to avoid GHG emissions?

No

C5. Emissions methodology

C5.1

(C5.1) Provide your base year and base year emissions (Scopes 1 and 2).

Scope 1

Base year start

January 1, 2012

Base year end

December 31, 2012

Base year emissions (metric tons CO₂e)

1,013,169

Comment

Base year emissions were updated in 2019 due to a baseline adjustment to account for the divestiture of Pfizer's Consumer Health division.

Scope 2 (location-based)

Base year start

January 1, 2012

Base year end

December 31, 2012

Base year emissions (metric tons CO₂e)

992,561

Comment

Base year emissions were updated in 2019 due to a baseline adjustment to account for the divestiture of Pfizer's Consumer Health division.

Scope 2 (market-based)

Base year start

January 1, 2012

Base year end

December 31, 2012

Base year emissions (metric tons CO₂e)

992,561

Comment

The location-based result has been used as a proxy since a market-based method did not exist in 2012 and the figure cannot be calculated.

C5.2

(C5.2) Select the name of the standard, protocol, or methodology you have used to collect activity data and calculate emissions.

The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (Revised Edition)

C6. Emissions data

C6.1

(C6.1) What were your organization's gross global Scope 1 emissions in metric tons CO₂e?

Reporting year

Gross global Scope 1 emissions (metric tons CO₂e)

734,638

Start date

January 1, 2019

End date

December 31, 2019

Comment

Past year 1

Gross global Scope 1 emissions (metric tons CO₂e)

720,945

Start date

January 1, 2018

End date

December 31, 2018

Comment

C6.2

(C6.2) Describe your organization's approach to reporting Scope 2 emissions.

Row 1

Scope 2, location-based

We are reporting a Scope 2, location-based figure

Scope 2, market-based

We are reporting a Scope 2, market-based figure

Comment

C6.3

(C6.3) What were your organization's gross global Scope 2 emissions in metric tons CO₂e?

Reporting year

Scope 2, location-based

762,286

Scope 2, market-based (if applicable)

634,205

Start date

January 1, 2019

End date

December 31, 2019

Comment

Past year 1

Scope 2, location-based

853,302

Scope 2, market-based (if applicable)

838,518

Start date

January 1, 2018

End date

December 31, 2018

Comment

C6.4

(C6.4) Are there any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1 and Scope 2 emissions that are within your selected reporting boundary which are not included in your disclosure?

No

C6.5

(C6.5) Account for your organization's gross global Scope 3 emissions, disclosing and explaining any exclusions.

Purchased goods and services

Evaluation status

Relevant, calculated

Metric tonnes CO₂e

3,794,093

Emissions calculation methodology

Emissions calculated based on 2019 spend data using DEFRA Table 13 emission factors. Spend data is extracted from Pfizer's accounting system by category. Spend associated with purchased goods and services with an associated GHG footprint is segregated by product or service type and multiplied by the most appropriate emission factor from DEFRA Table 13 (converted to USD) to estimate emissions (CO₂ eq). Spend not considered to have a significant Scope 3 GHG footprint (e.g. colleague wages, customer rebates, taxes, etc.) were excluded from the calculation.

Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

Please explain

Emission factor reference:

UK DEFRA Table 13:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/404542/Table_13_Indirect_emissions_from_supply_chain_2007-2011.xls

Capital goods

Evaluation status

Relevant, calculated

Metric tonnes CO₂e

345,953

Emissions calculation methodology

Emissions calculated based on 2019 spend data using DEFRA Table 13 emission factors. Spend data is extracted from Pfizer's accounting system by category. Spend associated with capital goods is segregated by product type and multiplied by the most appropriate emission factor from DEFRA Table 13 (converted to USD) to estimate emissions (CO₂ eq).

Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

Please explain

Emission factor reference:

UK DEFRA Table 13:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/404542/Table_13_Indirect_emissions_from_supply_chain_2007-2011.xls

Fuel-and-energy-related activities (not included in Scope 1 or 2)

Evaluation status

Relevant, calculated

Metric tonnes CO₂e

252,909

Emissions calculation methodology

Emissions calculated using stationary and mobile fuels consumption reported by operations within Pfizer's control. For fuels, consumption by fuel type (in MWh) was multiplied by the appropriate emission factors to determine GHG emissions. Emissions from UK sources calculated using UK Government GHG Conversion Factors for Company Reporting (2020) and include CO₂, CH₄ and N₂O (CO₂eq). For electricity, heat and steam, WTT emissions globally were calculated using UK Government Conversion Factors for Company Reporting. Emissions associated with transportation and distribution losses for the UK were calculated using UK factors for sites in the UK and using IEA CO₂ emissions from fuel combustion 2017 for the rest of the world. T&D losses calculated using IEA factors include CO₂ emissions only.

Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

Please explain

Emission factor references:

UK DEFRA 2020 Emission Factors:

<https://www.gov.uk/government/publications/greenhouse-gas-reporting-conversion-factors-2020>

(IEA emission factors purchased, subject to license agreement)

Upstream transportation and distribution

Evaluation status

Relevant, calculated

Metric tonnes CO₂e

873,030

Emissions calculation methodology

Data for international and some domestic transportation and distribution services purchased by Pfizer is obtained from our Intercompany Operations (IO) team and includes shipment mode, origin and destination, mass of goods, and total distance travelled. Data is not available for domestic US truck transportation and was not included in the emissions calculation. Emissions calculated using the distance, shipment weight and average GHG Protocol emission factor for each mode of transport for the US, UK and rest of world. Emissions associated with the transportation of goods purchased from our Tier 1 suppliers (e.g., raw materials, packaging materials) are excluded as they are included in Category 1, Purchased Goods and Services.

Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

Please explain

Emission factor reference:

GHG Protocol Emission Factors from Cross Sector Tools (2017):

Emission_Factors_from_Cross_Sector_Tools_March_2017.xlsx

Waste generated in operations

Evaluation status

Relevant, calculated

Metric tonnes CO₂e

16,420

Emissions calculation methodology

Emissions (CO₂eq) calculated using waste disposal and wastewater discharge data reported by operations within Pfizer's control and UK Government GHG Conversion Factors for Company Reporting (2020). Emission factors include collection, transportation and landfill emissions ('gate to grave') for waste sent to landfill. For combustion and recycling, the factors consider transport to an energy recovery or material reclamation facility only. Because most of the waste reported by sites as "other disposal" by Pfizer locations was sent to wastewater treatment, the wastewater treatment emission factor was used to estimate emissions for all waste reported in this category.

Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

Please explain

Emission factor reference:

UK DEFRA 2020 Emission Factors:

<https://www.gov.uk/government/publications/greenhouse-gas-reporting-conversion-factors-2020>

Business travel

Evaluation status

Relevant, calculated

Metric tonnes CO₂e

195,718

Emissions calculation methodology

Emissions associated with air travel calculated by Pfizer's travel agency based on distance travelled and class of service using GHG Protocol emission factors. Emissions associated with hotel stays where country of stay was available were estimated using DEFRA 2020 emission factors. Emissions for all other hotel stays were estimated using an average emission factor calculated based on DEFRA emission factors for those countries where Pfizer operates. Emissions associated with rental car use outside the US calculated using mileage data provided by the vendor using the DEFRA emission factor for average car, unknown fuel type. Emissions from US car rentals calculated from mileage provided by the vendor using US EPA 2020 GHG emission factors. Emissions estimated for US intercity rail travel (Amtrak) using 2018 US EPA Climate Leaders GHG emission factors for commuter rail. Emissions for rail travel outside the US calculated using the DEFRA emission factor for national rail. Air travel emissions include CO₂ only; all other travel-related emissions calculated as CO₂eq.

Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

Please explain

Emission factor references:

GHG Protocol Emission Factors from Cross Sector Tools (Reference-EF Public tab; 2017): Emission_Factors_from_Cross_Sector_Tools_March_2017.xlsx

US EPA 2020 GHG Emission Factors: <https://www.epa.gov/sites/production/files/2020-04/documents/ghg-emission-factors-hub.pdf>

UK DEFRA 2020 Emission Factors:

<https://www.gov.uk/government/publications/greenhouse-gas-reporting-conversion-factors-2020>

Employee commuting

Evaluation status

Relevant, calculated

Metric tonnes CO₂e

60,645

Emissions calculation methodology

Emissions estimated based on Pfizer's employee headcount as of June 30, 2019. Commuting distance for all colleagues estimated based on data published by NationMaster using the median distance per region to estimate for countries not covered by the source data. Commuting methods for North American colleagues estimated

based on a study published by Bloomberg in 2019. Commuting method assumptions for colleagues outside North America were made based on general knowledge of the region. Emissions associated with employee commuting in North America were calculated using US EPA Climate Leaders GHG 2020 emission factors. Emissions for all other regions were calculated using DEFRA emission factors (average car, unknown fuel type; national rail; light rail and tram; and average local bus).

Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

Please explain

References:

NationMaster Commuting Distances: <https://www.nationmaster.com/country-info/stats/Transport/Commute/Distance>

Bloomberg: www.bloomberg.com/news/articles/2019-01-22/how-americans-commute-to-work-in-maps

US EPA 2020 GHG Emission Factors: <https://www.epa.gov/sites/production/files/2020-04/documents/ghg-emission-factors-hub.pdf>

UK DEFRA 2020 Emission Factors:

<https://www.gov.uk/government/publications/greenhouse-gas-reporting-conversion-factors-2020>

Upstream leased assets

Evaluation status

Relevant, calculated

Metric tonnes CO2e

36,273

Emissions calculation methodology

Leased facility square footage for sites not within Pfizer's operational control derived from Pfizer's corporate real estate database. Emissions estimated using the Greenhouse Gas Protocol/Quantis Scope 3 Evaluator.

Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

Please explain

Reference:

Scope 3 Evaluator: <https://ghgprotocol.org/scope-3-evaluator>

Downstream transportation and distribution

Evaluation status

Relevant, calculated

Metric tonnes CO2e

99,576

Emissions calculation methodology

Emissions estimated based on number of products sold and average distance of travel to medical offices, pharmacies and retailers in the US only using DEFRA emission factors.

Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

Please explain

Processing of sold products

Evaluation status

Not relevant, explanation provided

Please explain

Pfizer products are not further processed in significant quantities.

Use of sold products

Evaluation status

Not relevant, explanation provided

Please explain

Pfizer products are not likely to create significant emissions in normal use.

End of life treatment of sold products

Evaluation status

Not relevant, explanation provided

Please explain

Pfizer products are intended to be ingested by humans. Products returned to Pfizer for destruction by Pfizer are accounted for in waste treatment estimate.

Downstream leased assets

Evaluation status

Not relevant, explanation provided

Please explain

Pfizer was not a significant real estate lessor in 2019.

Franchises

Evaluation status

Not relevant, explanation provided

Please explain

Pfizer does not operate franchises.

Investments

Evaluation status

Relevant, calculated

Metric tonnes CO2e

33,892

Emissions calculation methodology

Pfizer has interest in two joint ventures. One of these, located in India, reports energy consumption data directly in Pfizer's environmental data collection tool (Enablon) and the system is used to calculate Scope 1+2 emissions for the site. Pfizer also owns a 32% interest in a Consumer Health joint venture with GlaxoSmithKline (GSK). Sites included in the joint venture were part of Pfizer's internal network through Q2 2019 and continued to report energy consumption data into the Enablon system through most of the year. Emissions were estimated based on prior data if not provided by the site. The Enablon system was used to perform emission calculations. Total also includes emissions associated with Scope 3 upstream transportation for Consumer sites during the portion of the year that these sites were part of Pfizer's network. Emissions associated with other Pfizer investments are not included in the calculation.

Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

Please explain

Other (upstream)

Evaluation status

Not relevant, explanation provided

Please explain

Scope 3 emissions adequately captured by standard categories.

Other (downstream)

Evaluation status

Not relevant, explanation provided

Please explain

Scope 3 emissions adequately captured by standard categories.

C6.7

(C6.7) Are carbon dioxide emissions from biogenic carbon relevant to your organization?

Yes

C6.7a

(C6.7a) Provide the emissions from biogenic carbon relevant to your organization in metric tons CO2.

	CO2 emissions from biogenic carbon (metric tons CO2)	Comment
Row 1	220.3	

C6.10

(C6.10) Describe your gross global combined Scope 1 and 2 emissions for the reporting year in metric tons CO2e per unit currency total revenue and provide any additional intensity metrics that are appropriate to your business operations.

Intensity figure

0.00002893

Metric numerator (Gross global combined Scope 1 and 2 emissions, metric tons CO2e)

1,496,924

Metric denominator

unit total revenue

Metric denominator: Unit total

51,750,000,000

Scope 2 figure used

Location-based

% change from previous year

1.4

Direction of change

Decreased

Reason for change

Achieved from efficiency improvements. In 2019, we implemented 66 projects that included HVAC optimization, compressed air optimization, heat recovery, lighting upgrades and chilled water system improvements. These resulted in annual emissions reductions of 47,543 metric tons of GHG which accounted for the overall decrease.

C7. Emissions breakdowns

C7.1

(C7.1) Does your organization break down its Scope 1 emissions by greenhouse gas type?

Yes

C7.1a

(C7.1a) Break down your total gross global Scope 1 emissions by greenhouse gas type and provide the source of each used greenhouse warming potential (GWP).

Greenhouse gas	Scope 1 emissions (metric tons of CO2e)	GWP Reference
CO2	674,142	IPCC Fifth Assessment Report (AR5 – 100 year)
CH4	542	IPCC Fifth Assessment Report (AR5 – 100 year)
N2O	2,000	IPCC Fifth Assessment Report (AR5 – 100 year)
SF6	621	IPCC Fifth Assessment Report (AR5 – 100 year)
HFCs	38,327.2	IPCC Fifth Assessment Report (AR5 – 100 year)
Other, please specify VOC	14,476	Other, please specify Internal calculation method

C7.2

(C7.2) Break down your total gross global Scope 1 emissions by country/region.

Country/Region	Scope 1 emissions (metric tons CO2e)
United States of America	424,047
Puerto Rico	26,912
Ireland	65,414
India	14,579
China	4,390
Italy	39,717
Other, please specify Rest of World	159,579

C7.3

(C7.3) Indicate which gross global Scope 1 emissions breakdowns you are able to provide.

By business division

C7.3a

(C7.3a) Break down your total gross global Scope 1 emissions by business division.

Business division	Scope 1 emissions (metric ton CO2e)
Commercial Offices	28,932
Logistics	3,132
Pfizer Global Supply (Manufacturing)	439,913
Research and Development	144,426
Fleet	115,568
Historical Sites	1,809
Other Sites	856

C7.5

(C7.5) Break down your total gross global Scope 2 emissions by country/region.

Country/Region	Scope 2, location-based (metric tons CO2e)	Scope 2, market-based (metric tons CO2e)	Purchased and consumed electricity, heat, steam or cooling (MWh)	Purchased and consumed low-carbon electricity, heat, steam or cooling accounted for in Scope 2 market-based approach (MWh)
United States of America	419,368	358,892	957,403	32,691
Puerto Rico	72,804	72,804	108,481	0
Ireland	46,480	0	110,913	110,913
India	46,758	46,758	60,301	0
China	42,485	31,897	95,038	0
Italy	4,524	6,411	13,156	0
Other, please specify Rest of World	129,866	117,442	378,309	35,094

C7.6

(C7.6) Indicate which gross global Scope 2 emissions breakdowns you are able to provide.

By business division

C7.6a

(C7.6a) Break down your total gross global Scope 2 emissions by business division.

Business division	Scope 2, location-based (metric tons CO2e)	Scope 2, market-based (metric tons CO2e)
Commercial offices	35,174	23,526
Logistics	6,791	7,308
Pfizer Global Supply (Manufacturing)	632,532	529,277
Research and Development	75,137	61,449
Historical Sites	11,339	11,339
Other Sites	1,312	1,305

C7.9

(C7.9) How do your gross global emissions (Scope 1 and 2 combined) for the reporting year compare to those of the previous reporting year?

Decreased

C7.9a

(C7.9a) Identify the reasons for any change in your gross global emissions (Scope 1 and 2 combined), and for each of them specify how your emissions compare to the previous year.

	Change in emissions (metric tons CO2e)	Direction of change	Emissions value (percentage)	Please explain calculation
Change in renewable energy consumption	0	No change	0	Not applicable
Other emissions reduction activities	47,543	Decreased	3	Change equals total decrease in emissions in 2019 divided by baseline-adjusted total Scope 1+2 emissions for 2018, multiplied by 100

				to get percent= $(47,543/1,574,247)*100$
Divestment	0	No change	0	Not applicable
Acquisitions	0	No change	0	Not applicable
Mergers	0	No change	0	Not applicable
Change in output	29,780	Decreased	1.9	Change equals total decrease in emissions in 2019 divided by baseline adjusted total Scope 1+2 emissions for 2018, multiplied by 100 to get percent = $29,780/1,574,247)*100$
Change in methodology	0	No change	0	Not applicable
Change in boundary	0	No change	0	Not applicable
Change in physical operating conditions	0	No change	0	Not applicable
Unidentified	0	No change	0	Not applicable
Other	0	No change	0	Not applicable

C7.9b

(C7.9b) Are your emissions performance calculations in C7.9 and C7.9a based on a location-based Scope 2 emissions figure or a market-based Scope 2 emissions figure?

Location-based

C8. Energy

C8.1

(C8.1) What percentage of your total operational spend in the reporting year was on energy?

More than 0% but less than or equal to 5%

C8.2

(C8.2) Select which energy-related activities your organization has undertaken.

Indicate whether your organization undertook this energy-related activity in the reporting year

Consumption of fuel (excluding feedstocks)	Yes
Consumption of purchased or acquired electricity	Yes
Consumption of purchased or acquired heat	Yes
Consumption of purchased or acquired steam	Yes
Consumption of purchased or acquired cooling	Yes
Generation of electricity, heat, steam, or cooling	Yes

C8.2a

(C8.2a) Report your organization's energy consumption totals (excluding feedstocks) in MWh.

	Heating value	MWh from renewable sources	MWh from non-renewable sources	Total (renewable and non-renewable) MWh
Consumption of fuel (excluding feedstock)	HHV (higher heating value)	47,456	3,429,719	3,477,175
Consumption of purchased or acquired electricity		129,656	1,281,774	1,411,430
Consumption of purchased or acquired heat		2,758	2,367	5,125
Consumption of purchased or acquired steam		13,593	225,628	239,221
Consumption of purchased or acquired cooling		0	67,825	67,825
Consumption of self-generated non-fuel renewable energy		20,861		20,861
Total energy consumption		214,324	5,007,313	5,221,637

C8.2b

(C8.2b) Select the applications of your organization’s consumption of fuel.

	Indicate whether your organization undertakes this fuel application
Consumption of fuel for the generation of electricity	Yes
Consumption of fuel for the generation of heat	Yes
Consumption of fuel for the generation of steam	Yes
Consumption of fuel for the generation of cooling	No
Consumption of fuel for co-generation or tri-generation	Yes

C8.2c

(C8.2c) State how much fuel in MWh your organization has consumed (excluding feedstocks) by fuel type.

Fuels (excluding feedstocks)

Biodiesel

Heating value

LHV (lower heating value)

Total fuel MWh consumed by the organization

136

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

0

MWh fuel consumed for self-cogeneration or self-trigeneration

0

Emission factor

0.25243

Unit

metric tons CO₂e per MWh

Emissions factor source

GHG Protocol 2014 Cross Sector Tools

Comment

Fuels (excluding feedstocks)

Coal

Heating value

LHV (lower heating value)

Total fuel MWh consumed by the organization

107,431

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

107,431

MWh fuel consumed for self-cogeneration or self-trigeneration

0

Emission factor

0.32068

Unit

metric tons CO₂e per MWh

Emissions factor source

GHG Protocol 2014 Cross Sector Tools

Comment

Fuels (excluding feedstocks)

Fuel Oil Number 2

Heating value

LHV (lower heating value)

Total fuel MWh consumed by the organization

693

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

693

MWh fuel consumed for self-generation of steam

0

MWh fuel consumed for self-cogeneration or self-trigeneration

0

Emission factor

0.25685

Unit

metric tons CO₂e per MWh

Emissions factor source

GHG Protocol 2014 Cross Sector Tools

Comment

Fuels (excluding feedstocks)

Kerosene

Heating value

LHV (lower heating value)

Total fuel MWh consumed by the organization

72,312

MWh fuel consumed for self-generation of electricity

13,899

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

58,414

MWh fuel consumed for self-cogeneration or self-trigeneration

0

Emission factor

0.25325

Unit

metric tons CO₂e per MWh

Emissions factor source

GHG Protocol 2014 Cross Sector Tools

Comment

Fuels (excluding feedstocks)

Natural Gas

Heating value

LHV (lower heating value)

Total fuel MWh consumed by the organization

2,692,550

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

2,011,680

MWh fuel consumed for self-cogeneration or self-trigeneration

680,870

Emission factor

0.18123

Unit

metric tons CO₂e per MWh

Emissions factor source

GHG Protocol 2014 Cross Sector Tools

Comment

Fuels (excluding feedstocks)

Propane Liquid

Heating value

LHV (lower heating value)

Total fuel MWh consumed by the organization

111,933

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

111,642

MWh fuel consumed for self-cogeneration or self-trigeneration

0

Emission factor

0.22715

Unit

metric tons CO₂e per MWh

Emissions factor source

GHG Protocol 2014 Cross Sector Tools

Comment

Total use includes propane used by fleet vehicles.

Fuels (excluding feedstocks)

Wood Pellets

Heating value

LHV (lower heating value)

Total fuel MWh consumed by the organization

6,627

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

6,627

MWh fuel consumed for self-cogeneration or self-trigeneration

0

Emission factor

0.00392

Unit

metric tons CO2e per MWh

Emissions factor source

GHG Protocol 2014 Cross Sector Tools

Comment

Fuels (excluding feedstocks)

Diesel

Heating value

LHV (lower heating value)

Total fuel MWh consumed by the organization

119,826

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

0

MWh fuel consumed for self-cogeneration or self-trigeneration

0

Emission factor

0.2619

Unit

metric tons CO2e per MWh

Emissions factor source

GHG Protocol 2014 Cross Sector Tools

Comment

Fuels (excluding feedstocks)

Other, please specify
Ethanol (E100)

Heating value

LHV (lower heating value)

Total fuel MWh consumed by the organization

2,097

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

0

MWh fuel consumed for self-cogeneration or self-trigeneration

0

Emission factor

0.24994

Unit

metric tons CO₂e per MWh

Emissions factor source

GHG Protocol 2014 Cross Sector Tools

Comment

Fuels (excluding feedstocks)

Other, please specify

Ethanol (E85)

Heating value

LHV (lower heating value)

Total fuel MWh consumed by the organization

471

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

0

MWh fuel consumed for self-cogeneration or self-trigeneration

0

Emission factor

0.24875

Unit

metric tons CO₂e per MWh

Emissions factor source

GHG Protocol 2014 Cross Sector Tools

Comment

Fuels (excluding feedstocks)

Motor Gasoline

Heating value

LHV (lower heating value)

Total fuel MWh consumed by the organization

276,410

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

0

MWh fuel consumed for self-cogeneration or self-trigeneration

0

Emission factor

0.24415

Unit

metric tons CO₂e per MWh

Emissions factor source

GHG Protocol 2014 Cross Sector Tools

Comment

Fuels (excluding feedstocks)

Jet Kerosene

Heating value

LHV (lower heating value)

Total fuel MWh consumed by the organization

45,997

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

0

MWh fuel consumed for self-cogeneration or self-trigeneration

0

Emission factor

0.26203

Unit

metric tons CO₂e per MWh

Emissions factor source

GHG Protocol 2014 Cross Sector Tools

Comment

Fuels (excluding feedstocks)

Wood Chips

Heating value

LHV (lower heating value)

Total fuel MWh consumed by the organization

40,693

MWh fuel consumed for self-generation of electricity

0

MWh fuel consumed for self-generation of heat

0

MWh fuel consumed for self-generation of steam

40,693

MWh fuel consumed for self-cogeneration or self-trigeneration

0

Emission factor

0.00393

Unit

metric tons CO2e per MWh

Emissions factor source

GHG Protocol 2014 Cross Sector Tools

Comment

C8.2d

(C8.2d) Provide details on the electricity, heat, steam, and cooling your organization has generated and consumed in the reporting year.

	Total Gross generation (MWh)	Generation that is consumed by the organization (MWh)	Gross generation from renewable sources (MWh)	Generation from renewable sources that is consumed by the organization (MWh)
Electricity	273,744	247,391	26,398	247,345
Heat	0	0	0	0
Steam	0	0	0	0
Cooling	0	0	0	0

C8.2e

(C8.2e) Provide details on the electricity, heat, steam, and/or cooling amounts that were accounted for at a zero emission factor in the market-based Scope 2 figure reported in C6.3.

Sourcing method

Green electricity products (e.g. green tariffs) from an energy supplier, not supported by energy attribute certificates

Low-carbon technology type

Wind

Country/region of consumption of low-carbon electricity, heat, steam or cooling

Ireland

MWh consumed accounted for at a zero emission factor

110,913

Comment

Wind generated electricity

Sourcing method

Unbundled energy attribute certificates, Guarantees of Origin

Low-carbon technology type

Wind

Country/region of consumption of low-carbon electricity, heat, steam or cooling

Sweden

MWh consumed accounted for at a zero emission factor

10,169

Comment

Wind generated electricity

Sourcing method

Unbundled energy attribute certificates, Guarantees of Origin

Low-carbon technology type

Wind

Country/region of consumption of low-carbon electricity, heat, steam or cooling

Spain

MWh consumed accounted for at a zero emission factor

8,574

Comment

Wind generated electricity

Sourcing method

Unbundled energy attribute certificates, Guarantees of Origin

Low-carbon technology type

Nuclear

Country/region of consumption of low-carbon electricity, heat, steam or cooling

United States of America

MWh consumed accounted for at a zero emission factor

32,691

Comment

Nuclear generated electricity

Sourcing method

Heat/steam/cooling supply agreement

Low-carbon technology type

Biomass

Country/region of consumption of low-carbon electricity, heat, steam or cooling

Sweden

MWh consumed accounted for at a zero emission factor

16,351

Comment

Biomass generated district heat and steam

C9. Additional metrics

C9.1

(C9.1) Provide any additional climate-related metrics relevant to your business.

Description

Waste

Metric value

102,700,000

Metric numerator

kg

Metric denominator (intensity metric only)

Not applicable

% change from previous year

9

Direction of change

Increased

Please explain

Pfizer has set a 2020 waste disposal reduction goal of 15% compared to a 2012 baseline. While waste disposal increased in 2019 as a result of increased production, Pfizer has reduced waste disposed by 15% compared to the 2012 baseline.

Description

Other, please specify
Water withdrawal (excluding NCCW)

Metric value

15,050,000

Metric numerator

cubic meters

Metric denominator (intensity metric only)

Not applicable

% change from previous year

2

Direction of change

Decreased

Please explain

Pfizer has set a 2020 water withdrawal (excluding non-contact cooling water) reduction goal of 5% compared to a 2012 baseline. As of 2019, Pfizer has reduced water withdrawal by 14% compared to the 2012 baseline.

C10. Verification

C10.1

(C10.1) Indicate the verification/assurance status that applies to your reported emissions.

	Verification/assurance status
Scope 1	Third-party verification or assurance process in place
Scope 2 (location-based or market-based)	Third-party verification or assurance process in place
Scope 3	Third-party verification or assurance process in place

C10.1a

(C10.1a) Provide further details of the verification/assurance undertaken for your Scope 1 emissions, and attach the relevant statements.

Verification or assurance cycle in place

Annual process

Status in the current reporting year

Complete

Type of verification or assurance

Limited assurance

Attach the statement

 ERM CVS 2020 CDP Assurance Statement Pfizer_FINAL.pdf

Page/ section reference

Page 1

Relevant standard

ISAE3000

Proportion of reported emissions verified (%)

100

C10.1b

(C10.1b) Provide further details of the verification/assurance undertaken for your Scope 2 emissions and attach the relevant statements.

Scope 2 approach

Scope 2 location-based

Verification or assurance cycle in place

Annual process

Status in the current reporting year

Complete

Type of verification or assurance

Limited assurance

Attach the statement

 ERM CVS 2020 CDP Assurance Statement Pfizer_FINAL.pdf

Page/ section reference

Page 1

Relevant standard

ISAE3000

Proportion of reported emissions verified (%)

100

C10.1c

(C10.1c) Provide further details of the verification/assurance undertaken for your Scope 3 emissions and attach the relevant statements.

Scope 3 category

Scope 3: Purchased goods and services

Verification or assurance cycle in place

Annual process

Status in the current reporting year

Complete

Type of verification or assurance

Limited assurance

Attach the statement

 ERM CVS 2020 CDP Assurance Statement Pfizer_FINAL.pdf

Page/section reference

Page 1

Relevant standard

ISAE3000

Proportion of reported emissions verified (%)

100

Scope 3 category

Scope 3: Capital goods

Verification or assurance cycle in place

Annual process

Status in the current reporting year

Complete

Type of verification or assurance

Limited assurance

Attach the statement

 ERM CVS 2020 CDP Assurance Statement Pfizer_FINAL.pdf

Page/section reference

Page 1

Relevant standard

ISAE3000

Proportion of reported emissions verified (%)

100

Scope 3 category

Scope 3: Fuel and energy-related activities (not included in Scopes 1 or 2)

Verification or assurance cycle in place

Annual process

Status in the current reporting year

Complete

Type of verification or assurance

Limited assurance

Attach the statement

 ERM CVS 2020 CDP Assurance Statement Pfizer_FINAL.pdf

Page/section reference

Page 1

Relevant standard

ISAE3000

Proportion of reported emissions verified (%)

100

Scope 3 category

Scope 3: Upstream transportation and distribution

Verification or assurance cycle in place

Annual process

Status in the current reporting year

Complete

Type of verification or assurance

Limited assurance

Attach the statement

 ERM CVS 2020 CDP Assurance Statement Pfizer_FINAL.pdf

Page/section reference

Page 1

Relevant standard

ISAE3000

Proportion of reported emissions verified (%)

100

Scope 3 category

Scope 3: Waste generated in operations

Verification or assurance cycle in place

Annual process

Status in the current reporting year

Complete

Type of verification or assurance

Limited assurance

Attach the statement

 ERM CVS 2020 CDP Assurance Statement Pfizer_FINAL.pdf

Page/section reference

Page 1

Relevant standard

ISAE3000

Proportion of reported emissions verified (%)

100

Scope 3 category

Scope 3: Business travel

Verification or assurance cycle in place

Annual process

Status in the current reporting year

Complete

Type of verification or assurance

Limited assurance

Attach the statement

 ERM CVS 2020 CDP Assurance Statement Pfizer_FINAL.pdf

Page/section reference

Page 1

Relevant standard

ISAE3000

Proportion of reported emissions verified (%)

100

Scope 3 category

Scope 3: Employee commuting

Verification or assurance cycle in place

Annual process

Status in the current reporting year

Complete

Type of verification or assurance

Limited assurance

Attach the statement

 ERM CVS 2020 CDP Assurance Statement Pfizer_FINAL.pdf

Page/section reference

Page 1

Relevant standard

ISAE3000

Proportion of reported emissions verified (%)

100

Scope 3 category

Scope 3: Upstream leased assets

Verification or assurance cycle in place

Annual process

Status in the current reporting year

Complete

Type of verification or assurance

Limited assurance

Attach the statement

 ERM CVS 2020 CDP Assurance Statement Pfizer_FINAL.pdf

Page/section reference

Page 1

Relevant standard

ISAE3000

Proportion of reported emissions verified (%)

100

Scope 3 category

Scope 3: Investments

Verification or assurance cycle in place

Annual process

Status in the current reporting year

Complete

Type of verification or assurance

Limited assurance

Attach the statement

 ERM CVS 2020 CDP Assurance Statement Pfizer_FINAL.pdf

Page/section reference

Page 1

Relevant standard

ISAE3000

Proportion of reported emissions verified (%)

100

C10.2

(C10.2) Do you verify any climate-related information reported in your CDP disclosure other than the emissions figures reported in C6.1, C6.3, and C6.5?

No, but we are actively considering verifying within the next two years

C11. Carbon pricing

C11.1

(C11.1) Are any of your operations or activities regulated by a carbon pricing system (i.e. ETS, Cap & Trade or Carbon Tax)?

Yes

C11.1a

(C11.1a) Select the carbon pricing regulation(s) which impacts your operations.

- EU ETS
- Ireland carbon tax
- Singapore carbon tax
- Other carbon tax, please specify
- UK CRC
- Other carbon tax, please specify
- Ireland Light Fuel Oil Carbon Tax

C11.1b

(C11.1b) Complete the following table for each of the emissions trading schemes you are regulated by.

EU ETS

% of Scope 1 emissions covered by the ETS

11

% of Scope 2 emissions covered by the ETS

0

Period start date

January 1, 2019

Period end date

December 31, 2019

Allowances allocated

49,462

Allowances purchased

33,158

Verified Scope 1 emissions in metric tons CO₂e

81,191

Verified Scope 2 emissions in metric tons CO₂e

0

Details of ownership

Facilities we own and operate

Comment

C11.1c

(C11.1c) Complete the following table for each of the tax systems you are regulated by.

Ireland carbon tax

Period start date

January 1, 2019

Period end date

December 31, 2019

% of total Scope 1 emissions covered by tax

8.1

Total cost of tax paid

1,347,457

Comment

Ireland Natural Gas Carbon Tax

Singapore carbon tax

Period start date

January 1, 2019

Period end date

December 31, 2019

% of total Scope 1 emissions covered by tax

3.9

Total cost of tax paid

104,400

Comment

Other carbon tax, please specify

Period start date

January 1, 2019

Period end date

December 31, 2019

% of total Scope 1 emissions covered by tax

0.06

Total cost of tax paid

9,823

Comment

Ireland Light Fuel Oil Carbon Tax

Other carbon tax, please specify

Period start date

January 1, 2019

Period end date

December 31, 2019

% of total Scope 1 emissions covered by tax

0.8

Total cost of tax paid

132,263

Comment

UK CRC

C11.1d

(C11.1d) What is your strategy for complying with the systems you are regulated by or anticipate being regulated by?

Pfizer's strategy is to set corporate carbon reduction goals which in turn drive the sites that are participating in these schemes to implement energy reduction projects and equipment upgrades to reduce their carbon footprint. For example, our Havant, UK site (impacted by the UK Carbon Reduction Commitment tax) conducted an assessment that identified energy savings opportunities which were implemented in 2018 and 2019 with a verified reduction of 11% of site energy consumption.

C11.2

(C11.2) Has your organization originated or purchased any project-based carbon credits within the reporting period?

Yes

C11.2a

(C11.2a) Provide details of the project-based carbon credits originated or purchased by your organization in the reporting period.

Credit origination or credit purchase

Credit origination

Project type

Energy efficiency: industry

Project identification

Cogeneration and conservation projects

Verified to which standard

Other, please specify

US Connecticut Class III RECs

Number of credits (metric tonnes CO₂e)

10,610.55

Number of credits (metric tonnes CO₂e): Risk adjusted volume

0

Credits cancelled

No

Purpose, e.g. compliance

Other, please specify

Sold to support cost-effective project implementation

Credit origination or credit purchase

Credit origination

Project type

Biomass energy

Project identification

Biomass Boiler

Verified to which standard

Other, please specify
US North Carolina RECs

Number of credits (metric tonnes CO2e)

7,355.89

Number of credits (metric tonnes CO2e): Risk adjusted volume

0

Credits cancelled

Yes

Purpose, e.g. compliance

Not applicable

C11.3

(C11.3) Does your organization use an internal price on carbon?

No, but we anticipate doing so in the next two years

C12. Engagement

C12.1

(C12.1) Do you engage with your value chain on climate-related issues?

Yes, our suppliers
Yes, our customers

C12.1a

(C12.1a) Provide details of your climate-related supplier engagement strategy.

Type of engagement

Information collection (understanding supplier behavior)

Details of engagement

Other, please specify
Collect information on environmental sustainability programs, energy use, GHG emissions, and emission/energy reduction goals.

% of suppliers by number

10

% total procurement spend (direct and indirect)

60

% of supplier-related Scope 3 emissions as reported in C6.5

10

Rationale for the coverage of your engagement

Leveraging published industry and company life cycle assessments (LCA), Pfizer identified the leading suppliers in the major product categories accounting for largest scope 3 environmental impacts – 45% manufacturing operations; 25% raw material suppliers; 25% packaging materials; and 1% transportation vendors. There was a clear delineation that working with the top 150 suppliers in these categories (key suppliers) would maximize our impact.

Impact of engagement, including measures of success

In 2015 Pfizer Executive Leadership endorsed a public supplier sustainability goal that by 2020 all key suppliers will track GHG emissions, waste generation and water consumption; and 90% will institute reduction goals by 2020. The Pfizer Annual Review publishes results of the annual supplier survey which indicates progress year on year. In 2019, 88% of key suppliers tracked emissions and 49% had established reduction goals.

Comment

Percent of suppliers by number estimated. Pfizer has been leading an industry effort since 2016 to standardize sustainability survey questions to suppliers as many suppliers provide services to a number of pharmaceutical companies. Because of the overlap of suppliers used, the coordination will ease burden on suppliers and has already increased supplier participation rates.

C12.1b

(C12.1b) Give details of your climate-related engagement strategy with your customers.

Type of engagement

Education/information sharing

Details of engagement

Other, please specify

Promote Pfizer's environmental sustainability achievements through our Customer Engagement Marketing team.

% of customers by number

1

% of customer - related Scope 3 emissions as reported in C6.5

0

Please explain the rationale for selecting this group of customers and scope of engagement

Pfizer's Customer Engagement Marketing team promotes environmental sustainability achievements through external communications (e.g., LinkedIn posts).

Impact of engagement, including measures of success

Posts receive varying levels of engagement from followers. An Earth Day post highlighting a significant reduction in the GHG footprint associated with the production of progesterone received over 3,000 views.

Type of engagement

Other, please specify

Provision of data, participation in customer engagement surveys

Details of engagement

Other, please specify

Pfizer provides requested environmental program and performance information to a number of customers via CDP Supply Chain, Ecodesk, and customer-specific questionnaires.

% of customers by number

1

% of customer - related Scope 3 emissions as reported in C6.5

0

Please explain the rationale for selecting this group of customers and scope of engagement

Engagement opportunities were driven by our customers.

Impact of engagement, including measures of success

Pfizer provides responses to environmental performance surveys to customers representing well over \$100M in revenue.

C12.3

(C12.3) Do you engage in activities that could either directly or indirectly influence public policy on climate-related issues through any of the following?

Trade associations

Funding research organizations

Other

C12.3b

(C12.3b) Are you on the board of any trade associations or do you provide funding beyond membership?

Yes

C12.3c

(C12.3c) Enter the details of those trade associations that are likely to take a position on climate change legislation.

Trade association

US Chamber of Commerce

Is your position on climate change consistent with theirs?

Mixed

Please explain the trade association's position

The U.S. Chamber of Commerce (Chamber) states their policy position on climate change on the Chamber website (<https://www.uschamber.com/addressing-climate-change>): "The climate is changing and humans are contributing to these changes. We believe that there is much common ground on which all sides of this discussion could come together to address climate change with policies that are practical, flexible, predictable, and durable. We believe in a policy approach that acknowledges the costs of action and inaction and the competitiveness of the U.S." economy.

How have you influenced, or are you attempting to influence their position?

Pfizer is one of a number of "like-minded" companies that established the Climate Solutions Working Group (CSWG) in 2017. The CSWG is a standalone group of Chamber members that collaborate to advance business interests in climate change solutions and engage within the Chamber on climate change issues. In 2019, Pfizer engaged as moderator of an NGO panel at a Chamber-led meeting of nearly 30 companies, and climate and energy experts at the Concordia summit, which was held during the UN General Assembly in New York.

In 2018, the CSWG worked with the Chamber to influence the Chamber's recently released climate policy statement. The statement, while a document of compromise, makes clear that climate change is a serious issue, a risk to businesses, and that inaction is not an option.

Trade association

Business Roundtable (BRT)

Is your position on climate change consistent with theirs?

Mixed

Please explain the trade association's position

BRT's position on climate change can be found on its website (<https://www.businessroundtable.org/policy-perspectives/energy-environment>): "Access to sustainable, reliable, affordable energy is fundamental to U.S. national and economic

security. Similarly, a clean and healthy environment is essential for economic prosperity now and in the long term. Business Roundtable supports policies that build on America's strengths in technology and energy diversity, encourage investment and innovation in our nation's vibrant energy sector, and preserve environmental quality for the 21st century and beyond."

In 2019 Pfizer's CEO signed the BRT Statement on the Purpose of a Corporation. The statement notes that the CEOs "...believe the free-market system is the best means of generating good jobs, a strong and sustainable economy, innovation, a healthy environment and economic opportunity for all" and share a commitment to all of our stakeholders including customers, employees, suppliers, communities and shareholders.

How have you influenced, or are you attempting to influence their position?

Pfizer participated in efforts to review and enhance the BRT climate change position in 2019. Pfizer's CEO signed the BRT Statement on the Purpose of a Corporation. Pfizer also participated in the 2017 Business Roundtable Sustainability Report, whereby CEOs shared how their companies have put people and technology to work to improve the quality of life in communities across America and around the world.

Trade association

International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

Is your position on climate change consistent with theirs?

Consistent

Please explain the trade association's position

The IFPMA recognizes the link between climate change and human health.
<http://www.ifpma.org/resource-centre/ifpma-statement-on-climate-change-and-health-2/>.

How have you influenced, or are you attempting to influence their position?

Pfizer has long recognized the link between climate change and health:
http://www.pfizer.com/files/responsibility/protecting_environment/Climate_Change_and_Human_Health.pdf Pfizer's position on climate change can also be found here:
https://www.pfizer.com/files/responsibility/protecting_environment/Pfizer-Climate-Change-Position-Statement.pdf

Trade association

National Association of Manufacturers (NAM)

Is your position on climate change consistent with theirs?

Mixed

Please explain the trade association's position

NAM's position on energy and GHG regulation can be found on the NAM webpage (<https://www.nam.org/issue/environment/>) and in their Environment Agenda (<https://www.nam.org/wp-content/uploads/2019/05/PolicyWhitePaper-Environment.pdf>).

How have you influenced, or are you attempting to influence their position?

In past years, Pfizer has shared its Climate Change Position Statement with NAM leadership. Pfizer's position on climate change can be found here: https://www.pfizer.com/files/responsibility/protecting_environment/Pfizer-Climate-Change-Position-Statement.pdf.

Trade association

American Legislative Exchange Council (ALEC)

Is your position on climate change consistent with theirs?

Mixed

Please explain the trade association's position

ALEC Energy Principles can be found on its website <https://www.alec.org/model-policy/alec-energy-principles/>

How have you influenced, or are you attempting to influence their position?

For its December 2017 session, ALEC had proposed an objectionable resolution to reopen the Environmental Protection Agency's 2009 endangerment finding for greenhouse gases. Before this session, Pfizer worked hard to defeat the resolution because it conflicted with our vision of responsible environmental actions and sought to undermine efforts to address the critical issue of climate change. As a result of the engagement of companies such as ours, the resolution was rightfully withdrawn. We are pleased with that outcome. Had Pfizer not been engaged within ALEC, we would not have had the chance to make our position known and be an agent of change. – Opinion Section Washington Post, December 20, 2017 by Ken Cole, Sr. Vice President US Government Relations.

https://www.washingtonpost.com/opinions/pfizer-and-upss-victory-on-climate-change/2017/12/19/eafd79c4-e43d-11e7-833f-155031558ff4_story.html?noredirect=on&utm_term=.2a0240545652.

Pfizer has continued to engage with ALEC and vote on resolutions in a manner aligned and consistent with our company's climate change position statement (https://www.pfizer.com/files/responsibility/protecting_environment/Pfizer-Climate-Change-Position-Statement.pdf).

Trade association

Numerous other trade associations across the globe

Is your position on climate change consistent with theirs?

Unknown

Please explain the trade association's position

Pfizer is a member of many trade associations across the world focusing on pharma, consumer health, medical and vaccine issues. We also work with numerous general business associations (such as Chambers of Commerce) and other public policy groups. We detail above the positions relating to a sample of certain trade associations of which we are a member; however, given the large number of groups involved we are unable to provide details on the climate change position of each and every group.

How have you influenced, or are you attempting to influence their position?

Pfizer's participation as a member of these various industry and trade groups comes with the understanding that we may not always agree with the positions of the larger organization and/or other members, and that we are committed to voicing our concerns as appropriate through our colleagues who serve on the boards and committees of these groups. However, Pfizer works in good faith with these organizations to make its position on climate change and other environmental issues known.

C12.3d

(C12.3d) Do you publicly disclose a list of all research organizations that you fund?

Yes

C12.3e

(C12.3e) Provide details of the other engagement activities that you undertake.

Pfizer sponsored CDP's Spring 2019 workshop. Pfizer is also an active member of the World Resources Institute's Corporate Consultative Group through which we gain insights into climate change policy, GHG accounting, water risk mapping, and other sustainability matters as well as share our expertise and experience on these issues. Pfizer is also a member of Business for Social Responsibility. In December 2015, Pfizer joined the Science Based Target (SBT) initiative as a company that had already established a SBT. At the time, Pfizer was one of only a handful of companies to receive this recognition for its existing goal, which was developed in 2012.

C12.3f

(C12.3f) What processes do you have in place to ensure that all of your direct and indirect activities that influence policy are consistent with your overall climate change strategy?

Pfizer is a member of several industry and trade groups that represent both the pharmaceutical industry and the business community at large in an effort to bring about consensus on broad policy issues that can impact Pfizer's business objectives and ability to serve patients. Pfizer's participation as a member of these various industry and trade groups comes with the understanding that we may not always agree with the positions of the larger organization and/or other members, and that we are committed to voicing our concerns as appropriate through our colleagues who serve on the boards and committees of these groups. However, Pfizer works in

good faith with these organizations to make its position on climate change and other environmental issues known.

REF:

http://www.pfizer.com/responsibility/grants_contributions/lobbying_and_political_contributions.jsp

Information related to criteria used for third party funding may be found at:

http://www.pfizer.com/files/third_party_funding_criteria.pdf

Pfizer's Climate Change Position Statement is attached and may be found at:

http://www.pfizer.com/files/responsibility/protecting_environment/Pfizer_Climate_Change_Position_Statement.pdf

C12.4

(C12.4) Have you published information about your organization's response to climate change and GHG emissions performance for this reporting year in places other than in your CDP response? If so, please attach the publication(s).

Publication

In mainstream reports

Status

Complete

Attach the document

 pfizer-2019-annual-review.pdf

Page/Section reference

Our Performance, p 39; Meeting Our Environmental Sustainability Goals, p 37

Content elements

Emissions figures

Emission targets

Other metrics

Other, please specify

Supply chain performance results

Comment

Report posted online at

https://www.pfizer.com/files/investors/financial_reports/annual_reports/2019/index.html

Publication

In mainstream reports

Status

Complete

Attach the document

 Pfizer 10-K.pdf

Page/Section reference

Business -> Environmental Matters, p 20

Content elements

Risks & opportunities

Comment

Available online at <https://investors.pfizer.com/financials/sec-filings/sec-filings-details/default.aspx?FilingId=13958533>

Publication

In voluntary communications

Status

Complete

Attach the document

 Pfizer_Climate_Change_Position_Statement.pdf

Page/Section reference

Full document

Content elements

Strategy

Comment

Pfizer's Climate Change Position Statement may be found at https://pfe-pfizercom-d8-prod.s3.amazonaws.com/responsibility/protecting_environment/Pfizer_Climate_Change_Position_Statement.pdf

Publication

In mainstream reports, incorporating the TCFD recommendations

Status

Complete

Attach the document

 pfizer-2019-annual-review.pdf

Page/Section reference

Task Force for Climate-Related Financial Disclosure, p 50

Content elements

Governance
Strategy
Risks & opportunities
Emission targets

Comment

Pfizer's 2019 TCFD report is posted here:
https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2019/our-performance/tcf-table/index.html

Publication

In voluntary communications

Status

Complete

Attach the document

 SustainabilityBondFramework.pdf

Page/Section reference

Full document

Content elements

Strategy

Comment

Available on Pfizer's website here: <https://pfe-pfizercom-d8-prod.s3.amazonaws.com/SustainabilityBondFramework.pdf>

C15. Signoff

C-FI

(C-FI) Use this field to provide any additional information or context that you feel is relevant to your organization's response. Please note that this field is optional and is not scored.

C15.1

(C15.1) Provide details for the person that has signed off (approved) your CDP climate change response.

	Job title	Corresponding job category
Row 1	Chief Financial Officer & Executive Vice President, Global Supply	Chief Financial Officer (CFO)

SC. Supply chain module

SC0.0

(SC0.0) If you would like to do so, please provide a separate introduction to this module.

SC0.1

(SC0.1) What is your company's annual revenue for the stated reporting period?

	Annual Revenue
Row 1	51,750,000,000

SC0.2

(SC0.2) Do you have an ISIN for your company that you would be willing to share with CDP?

Yes

SC0.2a

(SC0.2a) Please use the table below to share your ISIN.

	ISIN country code (2 letters)	ISIN numeric identifier and single check digit (10 numbers overall)
Row 1	US	7170811035

SC1.1

(SC1.1) Allocate your emissions to your customers listed below according to the goods or services you have sold them in this reporting period.

Requesting member

Johnson & Johnson

Scope of emissions

Scope 1

Allocation level

Facility

Allocation level detail

Allocation based on manufacturing operations at Pfizer's Kalamazoo, Michigan facility.

Emissions in metric tonnes of CO₂e

12

Uncertainty ($\pm\%$)

0

Major sources of emissions

Fuel used by manufacturing operations

Verified

Yes

Allocation method

Allocation based on the market value of products purchased

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated based on fuel consumption data reported by the Kalamazoo site. Allocation based % of total site revenue attributed to customer.

Requesting member

Johnson & Johnson

Scope of emissions

Scope 2

Allocation level

Facility

Allocation level detail

Allocation based on manufacturing operations at Pfizer's Kalamazoo, Michigan facility.

Emissions in metric tonnes of CO₂e

18

Uncertainty ($\pm\%$)

0

Major sources of emissions

Purchased electricity, steam and heat for manufacturing operations

Verified

Yes

Allocation method

Allocation based on the market value of products purchased

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated using location-based emission factors and energy consumption data reported by the Kalamazoo, MI site. Allocation based % of total site revenue attributed to customer.

Requesting member

NHS England

Scope of emissions

Scope 1

Allocation level

Company wide

Allocation level detail

Emissions in metric tonnes of CO₂e

8,816

Uncertainty (±%)

10

Major sources of emissions

Fuel used to support manufacturing, R&D and Commercial operations.

Verified

Yes

Allocation method

Allocation based on the market value of products purchased

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions based on fuel consumption data reported by sites within Pfizer's operational control.

Requesting member

NHS England

Scope of emissions

Scope 2

Allocation level

Company wide

Allocation level detail

Emissions in metric tonnes of CO₂e

9,147

Uncertainty (±%)

10

Major sources of emissions

Purchased electricity, steam and heat for manufacturing, R&D and Commercial operations.

Verified

Yes

Allocation method

Allocation based on the market value of products purchased

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated using location-based emission factors and energy consumption data reported by sites within Pfizer's operational control.

Requesting member

U.S. General Services Administration - OMB ICR #3090-0319

Scope of emissions

Scope 1

Allocation level

Company wide

Allocation level detail

Emissions in metric tonnes of CO₂e

30,120

Uncertainty (±%)

10

Major sources of emissions

Fuel used to support manufacturing, R&D and Commercial operations.

Verified

Yes

Allocation method

Allocation based on the market value of products purchased

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions based on fuel consumption data reported by sites within Pfizer's operational control.

Requesting member

U.S. General Services Administration - OMB ICR #3090-0319

Scope of emissions

Scope 2

Allocation level

Company wide

Allocation level detail

Emissions in metric tonnes of CO₂e

31,254

Uncertainty (±%)

10

Major sources of emissions

Purchased electricity, steam and heat for manufacturing, R&D and Commercial operations.

Verified

Yes

Allocation method

Allocation based on the market value of products purchased

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated using location-based emission factors and energy consumption data reported by sites within Pfizer's operational control.

Requesting member

CVS Health

Scope of emissions

Scope 1

Allocation level

Company wide

Allocation level detail

Emissions in metric tonnes of CO₂e

0

Uncertainty (±%)

100

Major sources of emissions

Fuel used to support manufacturing, R&D and Commercial operations.

Verified

Yes

Allocation method

Other, please specify

Unable to allocate due to lack of information

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

CVS Health does not purchase Pfizer products directly from Pfizer so we do not have sufficient information to allocate emissions.

Requesting member

CVS Health

Scope of emissions

Scope 2

Allocation level

Company wide

Allocation level detail

Emissions in metric tonnes of CO₂e

0

Uncertainty (±%)

100

Major sources of emissions

Purchased electricity, steam and heat for manufacturing, R&D and Commercial operations.

Verified

Yes

Allocation method

Other, please specify

Unable to allocate due to lack of information

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

CVS Health does not purchase Pfizer products directly from Pfizer so we do not have sufficient information to allocate emissions.

Requesting member

Target Corporation

Scope of emissions

Scope 1

Allocation level

Company wide

Allocation level detail

Emissions in metric tonnes of CO₂e

0

Uncertainty (±%)

100

Major sources of emissions

Fuel used to support manufacturing, R&D and Commercial operations.

Verified

Yes

Allocation method

Other, please specify

Unable to allocate due to lack of information

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

Target Corporation does not purchase Pfizer products directly from Pfizer so we do not have sufficient information to allocate emissions.

Requesting member

Target Corporation

Scope of emissions

Scope 2

Allocation level

Company wide

Allocation level detail

Emissions in metric tonnes of CO₂e

0

Uncertainty (±%)

100

Major sources of emissions

Purchased electricity, steam and heat for manufacturing, R&D and Commercial operations.

Verified

Yes

Allocation method

Other, please specify

Unable to allocate due to lack of information

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

Target Corporation does not purchase Pfizer products directly from Pfizer so we do not have sufficient information to allocate emissions.

Requesting member

Wal Mart de Mexico

Scope of emissions

Scope 1

Allocation level

Company wide

Allocation level detail

Emissions in metric tonnes of CO₂e

0

Uncertainty (±%)

100

Major sources of emissions

Fuel used to support manufacturing, R&D and Commercial operations.

Verified

Yes

Allocation method

Other, please specify

Unable to allocate due to lack of information

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

Wal Mart de Mexico does not purchase Pfizer products directly from Pfizer so we do not have sufficient information to allocate emissions.

Requesting member

Wal Mart de Mexico

Scope of emissions

Scope 2

Allocation level

Company wide

Allocation level detail

Emissions in metric tonnes of CO₂e

0

Uncertainty (±%)

100

Major sources of emissions

Purchased electricity, steam and heat for manufacturing, R&D and Commercial operations.

Verified

Yes

Allocation method

Other, please specify

Unable to allocate due to lack of information

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

Wal Mart de Mexico does not purchase Pfizer products directly from Pfizer so we do not have sufficient information to allocate emissions.

Requesting member

Walmart, Inc.

Scope of emissions

Scope 1

Allocation level

Company wide

Allocation level detail

Emissions in metric tonnes of CO₂e

0

Uncertainty (±%)

100

Major sources of emissions

Fuel used to support manufacturing, R&D and Commercial operations.

Verified

Yes

Allocation method

- Other, please specify
- Unable to allocate due to lack of information

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

Walmart does not purchase Pfizer products directly from Pfizer so we do not have sufficient information to allocate emissions.

Requesting member

Walmart, Inc.

Scope of emissions

Scope 2

Allocation level

Company wide

Allocation level detail

Emissions in metric tonnes of CO₂e

0

Uncertainty (±%)

100

Major sources of emissions

Purchased electricity, steam and heat for manufacturing, R&D and Commercial operations.

Verified

Yes

Allocation method

- Other, please specify
- Unable to allocate due to lack of information

Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

Walmart does not purchase Pfizer products directly from Pfizer so we do not have sufficient information to allocate emissions.

SC1.2

(SC1.2) Where published information has been used in completing SC1.1, please provide a reference(s).

The allocations provided in SC 1.1 are based on a revenue percentage (total sales to customer/total revenue). Where possible this calculation is based on the total revenue for a single site or group of sites. Where this information isn't available the calculation is based on the total sales/Pfizer's total revenue as published in annual financial reports.

SC1.3

(SC1.3) What are the challenges in allocating emissions to different customers, and what would help you to overcome these challenges?

Allocation challenges	Please explain what would help you overcome these challenges
Customer base is too large and diverse to accurately track emissions to the customer level	Better coordination/consolidation of customer spend data internally and/or the ability to normalize emissions based on production volume rather than spend

SC1.4

(SC1.4) Do you plan to develop your capabilities to allocate emissions to your customers in the future?

Yes

SC1.4a

(SC1.4a) Describe how you plan to develop your capabilities.

Pfizer continues to explore opportunities to normalize emissions across our diverse manufacturing operations. We are also looking to simplify processes for consolidating spend by customer.

SC2.1

(SC2.1) Please propose any mutually beneficial climate-related projects you could collaborate on with specific CDP Supply Chain members.

SC2.2

(SC2.2) Have requests or initiatives by CDP Supply Chain members prompted your organization to take organizational-level emissions reduction initiatives?

No

SC3.1

(SC3.1) Do you want to enroll in the 2020-2021 CDP Action Exchange initiative?

No

SC3.2

(SC3.2) Is your company a participating supplier in CDP's 2019-2020 Action Exchange initiative?

No

SC4.1

(SC4.1) Are you providing product level data for your organization's goods or services?

No, I am not providing data

Submit your response

In which language are you submitting your response?

English

Please confirm how your response should be handled by CDP

	I am submitting to	Public or Non-Public Submission	Are you ready to submit the additional Supply Chain Questions?
I am submitting my response	Investors Customers	Public	Yes, submit Supply Chain Questions now

Please confirm below

I have read and accept the applicable Terms